ArticleTranslational cancer research2026
Low LAMA2 expression may affect drug resistance and prognosis in ovarian cancer via positive LGR5 coexpression.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug resistance often occurs during ovarian cancer (OC) treatment, and factors related to drug resistance often contribute to poor prognosis. Laminin subunit alpha 2 (LAMA2) can affect cancer progression, but its association with OC has rarely been studied. This study aimed to preliminarily investigate the expression of LAMA2 in OC and its ability to predict chemoresistance and patient prognosis using open-access big data and bioinformatics analysis. Methods: Data retrieved from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression Project (GTEx), and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) were used to analyze messenger ribonucleic acid (mRNA) and protein expression. Protein expression in OC tissues was detected using hematoxylin-eosin (HE) and immunohistochemistry (IHC). Up to 10,000 samples from 33 different cancer types and bivariate correlations were used to investigate the coexpression of the two genes. Gene expression with respect to tumor immune infiltration was determined using the R software package and TCGA data. Results: Likely modified by deoxyribonucleic acid (DNA) methylation, LAMA2 expression was significantly downregulated at the mRNA and protein levels in OC tissues and was consistently downregulated in 19 different tumors. Furthermore, LAMA2 expression was decreased in 90 platinum-resistant and cisplatin-resistant A2780 cells. A low level of LAMA2 predicted short overall survival (OS) and disease-free survival (DFS) in 149 OC patients and was related to low immune infiltration and high tumor grade. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the genes coexpressed with LAMA2 revealed that Rat sarcoma (Ras) protein signaling and other oncogene-related pathways were involved. LAMA2 was positively coexpressed with leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), aldehyde dehydrogenase 1 family member A1 (ALDH1A1), and von Willebrand factor (VWF) in 558 OC and 90 drug-resistant tissues and was coexpressed with these three genes in 19, 17, and 25 different tumors, respectively. Moreover, low LGR5 expression predicted short OS, and a combination of genes with LAMA2 could better predict short OS. Conclusions: Low LAMA2 expression is significantly associated with chemoresistance and poor prognosis in OC. This association may involve crosstalk with LGR5 and Ras signaling pathways. Thus, LAMA2 may represent a candidate biomarker for predicting treatment response and survival outcomes, warranting further preclinical and clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.